miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas

Archive ouverte

Gougelet, Angélique | Perez, Jennifer | Pissaloux, Daniel | Besse, Anthony | Duc, Adeline | Decouvelaere, Anne-Valérie | Ranchère-Vince, Dominique | Blay, Jean-Yves | Alberti, Laurent

Edité par CCSD ; Hindawi Publishing Corporation -

International audience. Sarcomas are divided into a group with specific alterations and a second presenting a complex karyotype, sometimes difficult to diagnose or with few therapeutic options available. We assessed if miRNA profiling by TaqMan low density arrays could predict the response of undifferentiated rhabdomyosarcoma (RMS) and osteosarcoma to treatment. We showed that miRNA signatures in response to a therapeutic agent (chemotherapy or the mTOR inhibitor RAD-001) were cell and drug specific on cell lines and a rat osteosarcoma model. This miRNA signature was related to cell or tumour sensitivity to this treatment and might be not due to chromosomal aberrations, as revealed by a CGH array analysis of rat tumours. Strikingly, miRNA profiling gave promising results for patient rhabdomyosarcoma, discriminating all types of RMS: (Pax+) or undifferentiated alveolar RMS as well as embryonal RMS. As highlighted by these results, miRNA profiling emerges as a potent molecular diagnostic tool for complex karyotype sarcomas.

Suggestions

Du même auteur

Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response

Archive ouverte | Gougelet, Angélique | CCSD

International audience

Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions

Archive ouverte | Dadone-Montaudié, Bérengère | CCSD

International audience. Dermatofibrosarcoma protuberans is underlined by recurrent collagen type I alpha 1 chain-platelet-derived growth factor B chain (COL1A1-PDGFB) fusions but ~ 4% of typical dermatofibrosarcoma ...

Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Archive ouverte | Asmane, Irène | CCSD

International audience. AIMS: A minority of patients with advanced sarcoma achieve prolonged progression free survival (PFS) with insulin growth factor type 1 receptor (IGF-1R) monoclonal antibody (Ab) therapy. A bi...

Chargement des enrichissements...